"10.1371_journal.pone.0044498","plos one","2012-09-04T00:00:00Z","Maria Beconi; Omar Aziz; Kim Matthews; Lara Moumné; Catherine O’Connell; Dawn Yates; Steven Clifton; Hannah Pett; Julie Vann; Lynsey Crowley; Alan F Haughan; Donna L Smith; Ben Woodman; Gillian P Bates; Fred Brookfield; Roland W Bürli; George McAllister; Celia Dominguez; Ignacio Munoz-Sanjuan; Vahri Beaumont","CHDI Management/CHDI Foundation Inc., Los Angeles, California, United States of America; BioFocus, Saffron Walden, Essex, United Kingdom; Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom; Evotec (UK) Ltd., Abingdon, United Kingdom","Conceived and designed the experiments: MB OA KM LM DY GPB CD IMS RWB GM VB. Performed the experiments: OA KM LM COC SC HP JV LC AFH DLS BW FB. Analyzed the data: OA KM MB DY LM COC SC HP JV FB GPB VB. Contributed reagents/materials/analysis tools: FB. Wrote the paper: MB VB.","The authors have declared that no competing interests exist. CHDI Foundation is a not-for-profit biomedical research organization exclusively dedicated to discovering and developing therapeutics that slow the progression of Huntingtons disease. Evotec (UK) and BioFocus (UK) conducted the research through a fee-for-service agreement for CHDI Foundation. This declaration does not alter the authors adherence to all PLoS ONE policies on sharing data and materials.","2012","09","Maria Beconi","MB",20,FALSE,11,12,12,2,TRUE,TRUE,FALSE,0,NA,FALSE
